AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Potassium channel subfamily K member 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P57789

UPID:

KCNKA_HUMAN

Alternative names:

Outward rectifying potassium channel protein TREK-2; TREK-2 K(+) channel subunit

Alternative UPACC:

P57789; B2R8T4; B2RCT3; B5TJL4; Q6B014; Q8TDK7; Q8TDK8; Q9HB59

Background:

The Potassium channel subfamily K member 10, known as TREK-2, is an outward rectifying potassium channel. It is characterized by its rapid activation and non-inactivating outward rectifier K(+) currents. TREK-2 is uniquely activated by arachidonic acid and other naturally occurring unsaturated free fatty acids, distinguishing it from other potassium channels.

Therapeutic significance:

Understanding the role of Potassium channel subfamily K member 10 could open doors to potential therapeutic strategies. Its unique activation mechanism and function in potassium ion transport make it a compelling target for drug discovery, aiming to modulate cellular excitability and related physiological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.